- Polyrizon Ltd. announced **positive pre-clinical results** for its PL-14 Allergy Blocker formulation, which is designed to prevent allergen penetration.  **[1893645_0001213900-25-096303_ea026036002ex99-1_polyrizon.htm:0]** 
- The study demonstrated that PL-14 effectively limited allergen diffusion, with only **1.07%** of the allergen passing through after one hour and **13.6%** after four hours, even when exposed to allergen loads estimated to be tens of times higher than typical real-world levels.  **[1893645_0001213900-25-096303_ea026036002ex99-1_polyrizon.htm:0]** 
- The company plans to **initiate clinical studies** for PL-14 and other candidates within its Capture & Contain (C&C) platform.  **[1893645_0001213900-25-096303_ea026036002ex99-1_polyrizon.htm:0]** 
- The Allergy Immunotherapy market is projected to grow from **$1.9 billion in 2025 to $4.2 billion by 2035**, expanding at a **7.9%** Compound Annual Growth Rate (CAGR).  **[1893645_0001213900-25-096303_ea026036002ex99-1_polyrizon.htm:0]**

Polyrizon Announces Positive Pre-Clinical Results for PL-14

- For the six months ended June 30, 2025, Polyrizon Ltd. reported a **net loss of $(177) thousand** and held **cash and cash equivalents of $15,828 thousand** as of June 30, 2025.  **[1893645_0001213900-25-088569_ea025666601ex99-1_polyrizon.htm:0]** **[1893645_0001213900-25-088569_ea025666601ex99-2_polyrizon.htm:10]** 
- The company believes its existing cash and cash equivalents will be sufficient to fund its operations until the **end of 2029**.  **[1893645_0001213900-25-088569_ea025666601ex99-2_polyrizon.htm:10]** **[1893645_0001213900-25-088569_ea025666601ex99-2_polyrizon.htm:11]** 
- Net cash provided by financing activities for the six months ended June 30, 2025, was **$15,097 thousand**, primarily due to a **$17.0 million private placement** closed in April 2025.  **[1893645_0001213900-25-088569_ea025666601ex99-1_polyrizon.htm:1]** **[1893645_0001213900-25-088569_ea025666601ex99-2_polyrizon.htm:5]** **[1893645_0001213900-25-088569_ea025666601ex99-2_polyrizon.htm:10]** 
- Polyrizon Ltd. effected a **1-for-250 reverse share split** on May 23, 2025, and formally regained compliance with Nasdaq's Minimum Bid Price Rule on **August 13, 2025**.  **[1893645_0001213900-25-088569_ea025666601ex99-2_polyrizon.htm:0]** **[1893645_0001213900-25-088569_ea025666601ex99-2_polyrizon.htm:5]** **[1893645_0001213900-25-088569_ea025666601ex99-1_polyrizon.htm:9]**

Polyrizon (PLRZ)